-
1
-
-
0029901109
-
Cost effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
-
Jonsson B, Johannesson M, Kjekshus J, et al. Cost effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
-
(1996)
Eur Heart J
, vol.17
, pp. 1001-1007
-
-
Jonsson, B.1
Johannesson, M.2
Kjekshus, J.3
-
2
-
-
0030965610
-
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia
-
Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997;10:787-94.
-
(1997)
Cardiovasc Drugs Ther
, vol.10
, pp. 787-794
-
-
Perreault, S.1
Hamilton, V.H.2
Lavoie, F.3
Grover, S.4
-
3
-
-
1842404801
-
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
-
Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
-
(1997)
N Engl J Med
, vol.336
, pp. 332-336
-
-
Johannesson, M.1
Jonsson, B.2
Kjekshus, J.3
-
4
-
-
0032559595
-
Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost effective?
-
Perreault S, Hamilton VH, Lavoie F, Grover SA. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost effective? Arch Intern Med 1998;158:375-81.
-
(1998)
Arch Intern Med
, vol.158
, pp. 375-381
-
-
Perreault, S.1
Hamilton, V.H.2
Lavoie, F.3
Grover, S.A.4
-
5
-
-
0033594134
-
Cost effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. Forecasting the incremental benefits of preventing coronary and cerebrovascular events
-
Grover SA, Coupal L, Paquet S, Zowall H. Cost effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
-
(1999)
Arch Intern Med
, vol.159
, pp. 593-600
-
-
Grover, S.A.1
Coupal, L.2
Paquet, S.3
Zowall, H.4
-
6
-
-
0030762162
-
Cost effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed care organization
-
Spearman ME, Summers K, Moore V, et al. Cost effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed care organization. Clin Ther 1997;19:582-602.
-
(1997)
Clin Ther
, vol.19
, pp. 582-602
-
-
Spearman, M.E.1
Summers, K.2
Moore, V.3
-
8
-
-
33751584473
-
Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety
-
Davidson MH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 1994;96(Suppl 6A):41S-4S.
-
(1994)
Am J Med
, vol.96
, Issue.SUPPL. 6A
-
-
Davidson, M.H.1
-
9
-
-
0026088892
-
Expanded clinical evaluation of lovastatin (EXCEL) study results .I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
-
Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results .I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
-
(1991)
Arch Intern Med
, vol.151
, pp. 43-49
-
-
Bradford, R.H.1
Shear, C.L.2
Chremos, A.N.3
-
10
-
-
0027507820
-
Effectiveness of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors
-
Behounek BD, McGovern ME, Kessler-Taub KB, et al. Effectiveness of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72: 1031-7.
-
(1993)
Am J Cardiol
, vol.72
, pp. 1031-1037
-
-
Behounek, B.D.1
McGovern, M.E.2
Kessler-Taub, K.B.3
-
11
-
-
0026540161
-
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia The Simvastatin and Lovastatin Multicenter Study Participants
-
Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992;14:708-17.
-
(1992)
Clin Ther
, vol.14
, pp. 708-717
-
-
Farmer, J.A.1
Washington, L.C.2
Jones, P.H.3
-
12
-
-
0027987849
-
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
-
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
-
(1994)
Lancet
, vol.344
, pp. 1383-1389
-
-
-
13
-
-
0030836029
-
Confidence intervals for cost-effectiveness ratios: A comparison of four methods
-
Polsky D, Click HE, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ 1997;6:243-52.
-
(1997)
Health Econ
, vol.6
, pp. 243-252
-
-
Polsky, D.1
Click, H.E.2
Willke, R.3
Schulman, K.4
|